Bevacizumab (avastin) for corneal neovascularization--corneal light shield soaked application.
To describe a case where topical bevacizumab (Avastin) was used in an attempt to reduce corneal neovascularization before corneal graft. Topical bevacizumab was applied through a corneal light shield for 20 minutes once a week for 11 weeks to the cornea. Corneal vascularization was not reduced. Topical bevacizumab was not effective in this case at reducing corneal neovascularization.